

Institute and Faculty of Actuaries

# What if there was a cure for obesity?


## Dr Matthew S Capehorn


GPwSI and Bariatric Physician Clinical Manager, Rotherham Institute for Obesity Board member, Association for the Study of Obesity (ASO)


### Nay Wynn


Research Actuary, Hannover Re


22 May 2018



































## Relative risk of health problems associated with obesity


Disease	Women	Men				
Type II Diabetes	12.7	5.2				
Hypertension	4.2	2.6				
Myocardial infarction	3.2	1.5				
Colon cancer	2.7	3.0				
Angina	1.8	1.8				
Gall bladder disease	1.8	1.8				
Ovarian cancer	1.7	-				
Osteoarthritis	1.4	1.9				
Stroke	1.3	1.3				
National Audit Office Report. Tackling Obesity in England. London, 2001						


































#### 13












#### 15


	Association of Pharmacolog A systematic review and me		tments for Obesity with Weight Loss & Adverse Events: sis - Khera R et al. <i>JAMA</i> , 2016	
	28 RCTs (29,018 patients			
•	Mean age 46 (74% wome	,	nt 100.5kg, BMI 36.1	
		,,		
•	Those reaching 5% weigh	nt loss:		
	<ul> <li>Placebo</li> </ul>	23%		
	<ul> <li>Phentermine/topiramate</li> </ul>	e 75%	8.8kg (7.42 – 10.20)	
	<ul> <li>Liraglutide</li> </ul>	63%	5.3kg (4.52 – 6.06)	
	<ul> <li>Naltrexone/bupropion</li> </ul>	55%	5.0kg (3.96 – 5.94)	
	<ul> <li>Lorcaserin</li> </ul>	49%	3.2kg (2.46 – 3.97)	
	<ul> <li>Orlistat</li> </ul>	44%	2.6kg (2.16 – 3.04)	









Device et al 4005		
Pories et.al. 1995	Gastric Bypass	89%
Torquati et al 2005	Gastric Bypass	74%
Schauer et.al. 2003	Gastric Bypass	82%
Sugerman et al 2003	Gastric Bypass	86%
Dixon et.al 2003	Lap Band	64%
Gagner (unpublished)	Sleeve Gastrectomy	65%
s that occurs from the changes in	fat mass and release of adipocytokines	,
NBSR showed that two ver	ars after primary surgery:	
in boit on on ou that the yet	alo altor primary ourgory	
	Schauer et.al. 2003 Sugerman et al 2003 Dixon et.al 2003 Gagner (unpublished) ent or resolution of diabetes caloric intake, leading to decrease that occurs from the changes in that occurs from the decrease of tine <sup>1</sup>	Schauer et.al. 2003       Gastric Bypass         Sugerman et al 2003       Gastric Bypass         Dixon et.al 2003       Lap Band         Gagner (unpublished)       Sleeve Gastrectomy         ent or resolution of diabetes is thought to be due to:         caloric intake, leading to decreased stimulation of incretins and insulin resolution of the changes in fat mass and release of adipocytokines         that occurs from the decrease of gut hormones(GLP1), resulting from the









### Modelling the impact on CI Hannover Re trends for CI vary by condition, however to simplify: Base scenario: zero trends - Starting point: 100% of lives with normal BMI - End point: 50% of lives with normal BMI and 50% obese • Run 1: allow for increase in rates over 30 years (~2050) • Run 2: allow for increase in rates over 20 years (~2040) The impact is determined by calculating levelised rates by age and term for various sex/smoker splits Summarise using a typical business mix to get a single percentage Institute and Faculty of Actuaries 22 May 2018


٦

Run 1 (ot	esity imp	pact ove	er 30 yea	ırs) assu	mes the following increase in trends:	
	Disease		Male	Female	<ul> <li>Slide 14 shows that the relative risk for female heart a</li> </ul>	attack for
H	eart attack		+0.7%	+2.5% •	someone obese was 3.2; assuming 50% at this rate a normal 1 rate, the average is 2.1.	ind 50% at
	Stroke		+0.5%	+0.5%	<ul> <li>The compound rate over 30 year works out at 2.5%.</li> </ul>	
Other d	Other digestive cancers		+0.5%	+0.5%		
Bre	Breast cancer	N/A	+0.2%	+0.2% – For cancers, the estimates comes from National Cancer Ins		
Upper aer	er aerodigestive cancers		+1.4%	+1.4%	but we follow a similar methodology to heart attack ar	id stroke
Overall in	npact:					
Run 1	MN	MS	FN	FS	Overall	
		2%	3%	3%	2%	

# Run 2: assumptions and impact

• Run 2 (obesity impact over 20 years) assumes the following increase in trends:

	Disease eart attack Stroke		Male +1.1% +0.7%	Female +3.8% ◄ +0.7%	someone c normal 1 ra	hows that the relative risk for female heart attack for bese was 3.2; assuming 50% at this rate and 50% at ate, the average is 2.1. bund rate over 20 year works out at 3.8%.
Other d	gestive car	ncers	+0.7%	+0.7%		-
Breast cancer	N/A	+0.4%		s, the estimates comes from National Cancer Institute		
Upper aerodigestive cancers		10.00/	+2.0%	but we follow a similar methodology to heart attack and strok		
	Ū	cancers	+2.0%	72.070		
	Ū	MS	+2.0%	FS	Overall	
Overall in	npact:				Overall 4%	Institute and Facult of Actuarie




## Impact on Term Assurance

- Historic reductions in smoker prevalence has had an impact on reducing mortality from cardiovascular diseases, stroke and cancers
  - would the rise of obesity prevalence reverse this?
  - could see start projecting mortality deteriorations in the future?
- NHS (June 2016) estimates that:
  - obesity reduces life expectancy by an average of 3 to 10 years, depending on severity
  - obesity and being overweight contribute to at least 1 in every 13 deaths in Europe
- Impact on TA may be less than CI?
  - you could be diagnosed with a heart attack/stroke as a result of your obesity (get a pay-out under CI) but still take preventative measures to delay death

22 May 2018

Institute

and Faculty of Actuaries



Questions	Comments
Expressions of individual views by members and its staff are encouraged.	of the Institute and Faculty of Actuaries
The views expressed in this presentation are	e those of the presenter.
	Institute and Faculty of Actuaries
22 May 2018	